A multilayer bioabsorbable construct is provided that includes at least one top layer, at least one chorion membrane layer, at least one basement layer, and at least one support layer between the chorion membrane layer and basement layer. Various therapeutic uses of the multilayer bioabsorbable construct are also provided.

Bioresorbable silk fibroin tracheal stents can be designed and engineered to maintain a tracheal opening. A tracheal stent will maintain a tracheal opening for a period while tissue structure and function is restored. Bioresorbable silk fibroin tracheal stents programmably degrade without negative biological or clinical outcomes. Bioresorbable silk fibroin tracheal stents do not need to be removed following tracheal restoration. Bioresorbable biopolymer tracheal stents can be internally or externally deployed. Bioresorbable biopolymer tracheal stents, for example can be internally or externally deployed in a patient. Such stents may be affixed to function as a splint with tunable mechanically properties to treat, for example, a patient with severe airway collapse.

A system for manufacturing a synthetic organ suitable for transplantation into a biological organism is provided. This synthetic organ includes a three-dimensional polymer scaffold, wherein the shape and dimensions of the polymer scaffold are based on a native organ, wherein the polymer scaffold further includes at least one layer of polymer fibers that have been deposited by electrospinning, and wherein the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both; and wherein the polymer scaffold has been preseeded with at least one type of biological cell prior to implantation into a biological organism, and wherein the at least one type of biological cell is operative to facilitate integration of the polymer scaffold into the organism so that the polymer scaffold may function in a manner significantly similar to or the same as the native organ.

Disclosed herein are methods involving the targeting of 5HT biosynthesis in gut insulin-negative cells to convert them into insulin-positive cells. Also, disclosed are methods for treating a disease or disorder in a mammal, preferably a human, associated with impaired pancreatic endocrine function, by administering a therapeutically effective amount of an enumerated active agent that reduces the expression, biosynthesis, signaling or biological activity of serotonin or increases its degradation, wherein administering comprises delivering the agent to Gut Ins cells in the mammal. Other embodiments of the method are directed to therapy wherein an agent that significantly reduces FOXO1 expression, biosynthesis, signaling or biological activity or increases its degradation is administered in addition to the agent that reduces serotonin, or alternatively an agent that reduces FOXO1 expression is targeted to serotonin-positive gut enteroendocrine cells.

A stent for anastomosis of different kinds of organs includes a main body, and at least one fixing unit provided in the main body. At least a portion of the main body is inserted into one of different kinds of organs to be anastomosed with each other, and the rest of the main body is inserted into the other of the different kinds of organs. A distance between the different kinds of organs under the anastomosis is maintained by the fixing units.

Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis, to improve blood flow to lung tissue, to regenerate, repair, and improve lung tissue damaged by lung disease, disorder and/or injury, and to protect lung tissue from damage caused by lung disease, disorder and/or injury in a patient.

An implant can include a plurality of polymeric fibers associated together into a fibrous body. The fibrous body is capable of being shaped to fit a tracheal defect and capable of being secured in place by suture or by bioadhesive. The fibrous body can have aligned fibers (e.g., circumferentially aligned) or unaligned fibers. The fibrous body can be electrospun. The fibrous body can have a first characteristic in a first gradient distribution across at least a portion of the fibrous body. The fibrous body can include one or more structural reinforcing members, such as ribbon structural reinforcing members, which can be embedded in the plurality of fibers. The fibrous body can include one or more structural reinforcing members bonded to the fibers with liquid polymer as an adhesive, the liquid polymer having a substantially similar composition of the fibers.

Provided is an artificial bladder including: a main body which includes an inlet port, an outlet port, and a predetermined reservoir portion configured to store urine between the inlet port and the outlet port and is formed of a biocompatible polymer that is expandable so that a volume of the reservoir portion changes according to the amount of urine; a sensor which is attached to an outer wall of the main body, has a surface having a wrinkled structure, and is provided so that, when the volume of the reservoir portion increases, the wrinkled structure stretches out and resistance of the sensor changes; and an actuator which is provided at the outlet port and is configured to discharge the urine according a result detected by the sensor.

Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, containing the donor cells. The donor cells may be a mixture of stem cells/progenitors with supporting early lineage stage mesenchymal cells. The patch graft promotes migration of the donor cells into the host organ and supports the successful integration of donor cells with host cells to repair the diseased organ.

The present invention relates to a composition for preventing or treating stenosis, in which the composition includes brown algae extract, and more particularly to a composition for preventing or treating stenosis, in which the composition includes brown algae-derived polyphenol as an active ingredient, thereby providing excellent prevention or treatment effect on stenosis including tracheal stenosis, glottic stenosis, vascular stenosis, and the like.